<SEC-DOCUMENT>0001571049-15-009169.txt : 20151112
<SEC-HEADER>0001571049-15-009169.hdr.sgml : 20151112
<ACCEPTANCE-DATETIME>20151112161039
ACCESSION NUMBER:		0001571049-15-009169
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20151112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20151112
DATE AS OF CHANGE:		20151112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		151224925

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1502678_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of the Securities Exchange Act of 1934
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Date of Report (Date of earliest event
reported): November 12, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter) </B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 31%; text-align: center"><FONT STYLE="font-size: 10pt"><B>000-50626</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD NOWRAP>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(State or other jurisdiction</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of incorporation)</B></P></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>(Commission File Number)</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(IRS Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>200 Connell
Drive, Suite 1500</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Berkeley Heights, NJ 07922 </B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices and zip code) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Former Name or Former Address, if Changed
Since Last Report)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; font-size: 10pt"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 97%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02 Results of Operations and Financial Condition.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibits attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached as Exhibit 99.1 is a copy of a
press release of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated November 12, 2015, announcing certain
financial results for the third quarter ended September 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will conduct a conference call
to review its financial results on November 12, 2015, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Form 8-K contains certain forward-looking
statements that involve risks and uncertainties that could cause actual results to be materially different from historical results
or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and intended utilization of Cyclacel&rsquo;s product candidates, the conduct
and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding
partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that
appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical
trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that
include the words &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;potential,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;intends,&rdquo; &ldquo;continues,&rdquo; &ldquo;forecast,&rdquo; &ldquo;designed,&rdquo; &ldquo;goal,&rdquo; or the negative
of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and
uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings
we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current
only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of
new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Exhibit<BR>
    Number</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 89%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press release announcing financial results for the third quarter ended September 30, 2015, dated November 12, 2015.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 12, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1502678_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: left"><IMG SRC="logo1.jpg" ALT=""></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: middle"><FONT STYLE="font: 10pt Arial, Helvetica, Sans-Serif">Cyclacel Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><IMG SRC="logo2.jpg" ALT=""></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Cyclacel Pharmaceuticals
Reports Third Quarter 2015 Financial Results</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><I>Conference
Call Scheduled November 12, 2015 at 4:30 p.m. EST</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">BERKELEY HEIGHTS, N.J., Nov. 12, 2015
- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (&quot;Cyclacel&quot; or the &quot;Company&quot;), a biopharmaceutical
company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious
disorders, today reported its financial results and business highlights for the third quarter ended September 30, 2015.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">The Company's net loss applicable
to common shareholders for the third quarter ended September 30, 2015 was $2.8 million, or $0.08 per basic and diluted share, compared
to a net loss applicable to common shareholders of $5.0 million, or $0.22 per basic and diluted share for the third quarter ended
September 30, 2014. As of September 30, 2015, cash and cash equivalents totaled $22.7 million.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&quot;SEAMLESS continues to progress
towards final data read-out,&rdquo; said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. &ldquo;There are now
approximately 8% of events remaining to occur and we anticipate reporting top-line data during the first half of 2016. Following
unblinding and analysis of the data, we will review the results to determine their suitability for submission to regulators. Our
CDK2/9 programs made significant progress over the quarter. The CYC065 Phase 1 trial in solid tumor and lymphoma patients has started
and the mechanistic rationale for CDK2/9 inhibition in targeted solid tumors and hematological malignancies is supported by multiple
presentations at scientific conferences. Seliciclib was administered to the first patients with Cushing&rsquo;s disease in an investigator-sponsored
trial. We and our investigators are excited about the prospects of CDK2/9 inhibitors and we look forward to keeping you apprised
as to our progress.&quot;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>Business Highlights</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>Sapacitabine in SEAMLESS, pivotal,
Phase 3 study for first-line treatment in elderly patients with acute myeloid leukemia (AML): </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 10.55pt 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify; padding-right: 10.55pt"><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">Continued follow-up
with 8% of events remaining before analyzing mature data and reporting top-line results. The SEAMLESS study is powered at 90% to
detect a 27.5% improvement of survival between the experimental and control arms.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>Cyclin Dependent Kinase (CDK)
Inhibitor Programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">Presented the molecular rationale for clinical development of CYC065
for the treatment of solid tumors at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">Dosed the first patient in a first-in-human, Phase 1 trial of CYC065,
the Company&rsquo;s second-generation CDK2/9 inhibitor, in solid tumor and lymphoma patients to evaluate the safety, tolerability
and pharmacokinetic profile of CYC065</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Wingdings">&#254;</FONT><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;&nbsp;&nbsp;200
Connell Drive, Suite 1500, Berkeley Heights, NJ&nbsp; 07922 USA T: +1 (908) 517 7330 F: +1 (866) 271 3466</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Wingdings">&#168;</FONT><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">&nbsp;&nbsp;&nbsp;Dundee
Technopole, James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><U>www.cyclacel.com</U> &ndash; <U>info@cyclacel.com</U></P>

<P STYLE="font: 7pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Symbol; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">Presented the molecular rationale for clinical development of CYC065
for the treatment of leukemias and lymphomas at the Society of Hematologic Oncology (SOHO) 2015 Annual Meeting</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">Dosed the first patient in a Phase 2 investigator-sponsored trial
(IST) evaluating seliciclib as a potential treatment for Cushing&rsquo;s disease.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif">CYC065 data to be presented at the upcoming <FONT STYLE="font-weight: normal">2015
San Antonio Breast Cancer Symposium in Texas and at the </FONT>4<SUP>th</SUP> Neuroblastoma Symposium in Newcastle Upon Tyne, United
Kingdom </FONT></TD></TR></TABLE>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>Third Quarter 2015 Financial Results</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>Revenue</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Revenue was $0.7 million for both
the three months ended September 30, 2014 and 2015. Revenue is mainly related to grants from the European Union and the Biomedical
Catalyst of the United Kingdom government. The Company recognized $0.3 million from its license and supply agreement with ManRos
during the three months ended September 30, 2015.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Research and development expenses
were $2.9 million for the three months ended September 30, 2015, compared to $5.0 million for the same period in the previous year.
The decrease was primarily a result of reduced expenditures in study and site startup costs associated with the SEAMLESS Phase
3 study this quarter compared to the same period last year.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">General and administrative expenses
for the three months ended September 30, 2015 were $1.2 million compared to $1.4 million for the same period in 2014. The decrease
was primarily the result of lower patent-related and stock-based compensation costs.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>Conference call and Webcast Information:</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Cyclacel will conduct a conference
call on November 12, 2015 at 4:30 p.m. Eastern Time to review the third quarter 2015 results. Conference call and webcast details
are as follows:</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">Conference call information:</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">US/Canada call: (877) 493-9121/ international call: (973) 582-2750</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">US/Canada archive: (800) 585-8367 / international archive:
(404) 537-3406</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">Code for live and archived conference call is 63652219</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">For the live and archived webcast,
please visit the Corporate Presentations and Events page on the Cyclacel website at <U>www.cyclacel.com</U>. The webcast will
be archived for 90 days and the audio replay for 7 days.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>About Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Cyclacel is a biopharmaceutical company
developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases.
Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase 3 trial being conducted under an
SPA with the FDA as front-line treatment for acute myeloid leukemia (AML) in the elderly, and other studies for</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Calibri (Body)"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">myelodysplastic syndromes (MDS),
chronic lymphocytic leukemia (CLL) and solid tumors including breast, lung, ovarian and pancreatic cancer and in particular those
patients carrying BRCA mutations. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology
and oncology based on a development pipeline of novel drug candidates. Please visit <U>www.cyclacel.com</U> for additional information.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>Forward-looking Statements</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">This news release contains certain
forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and
plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product
candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale
or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to
consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot;
&quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot;
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description
of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic
and other filings we file with the Securities and Exchange Commission and are available at <U>www.sec.gov</U>. Such forward-looking
statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Calibri (Body)"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL PHARMACEUTICALS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(In $000s, except share and per share
amounts)</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="border-bottom: black 1pt solid; font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>Three&nbsp;Months&nbsp;Ended</B></FONT><BR>
<FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>September 30,</B></FONT></TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="border-bottom: black 1pt solid; font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>Nine months&nbsp;Ended</B></FONT><BR>
<FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>September 30,</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>2014</B></FONT></TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>2015</B></FONT></TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>2014</B></FONT></TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>2015</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 47%; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Revenues:</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Grant revenue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">735</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">462</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">1,487</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">1,270</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Collaboration and research and development revenue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">253</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">253</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Total revenues</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">735</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">715</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">1,487</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">1,523</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Operating expenses:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Research and development</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">4,972</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">2,904</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">13,861</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">9,826</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">General and administrative</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">1,433</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">1,205</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">4,281</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">4,006</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Total operating expenses</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">6,405</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">4,109</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">18,142</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">13,832</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Operating loss</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(5,670</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(3,394</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(16,655</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(12,309</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Other income (expense):</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Change in valuation of financial instruments associated with stock purchase agreement</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(4</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(27</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(115</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(51</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Change in valuation of liabilities measured at fair value</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Foreign exchange gains (losses) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">219</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(23</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(354</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Interest income</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">5</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Other income, net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">13</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">26</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">95</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Total other income (expense)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">9</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">207</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(87</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(305</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Loss from continuing operations before taxes</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(5,661</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(3,187</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(16,742</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(12,614</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Income tax benefit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">750</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">478</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">2,135</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">1,646</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Net loss from continuing operations</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(4,911</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(2,709</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(14,607</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(10,968</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Discontinued operations:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Income from discontinued operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">29</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Income tax on discontinued operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(2</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(10</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Net income from discontinued operations</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">19</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Net loss</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(4,907</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(2,709</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(14,588</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(10,968</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Dividend on convertible exchangeable preferred shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(50</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(50</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(150</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(150</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Net loss applicable to common shareholders</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(4,957</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(2,759</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(14,738</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(11,118</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>Basic and diluted earnings per common share:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Net loss per share, continuing operations&thinsp;&ndash;&thinsp;basic and diluted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(0.22</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(0.08</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(0.68</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(0.35</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Net income per share, discontinued operations&thinsp;&ndash;&thinsp;basic and diluted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">0.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">0.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">0.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">0.00</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Net loss per share&thinsp;&ndash;&thinsp;basic and diluted</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(0.22</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(0.08</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(0.68</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(0.35</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Weighted average common shares outstanding</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">22,676,475</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">34,675,569</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">21,607,888</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">31,741,910</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Calibri (Body)"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(In $000s, except share, per share,
and liquidation preference amounts) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>December 31,</B></FONT></TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>September 30,</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>2014</B></FONT></TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>2015</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 8pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 8pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 8pt; text-align: center"><FONT STYLE="font: 8pt Calibri, Helvetica, Sans-Serif"><B>(Unaudited)</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>ASSETS</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Current assets:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Cash and cash equivalents</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">24,189</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">22,728</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Prepaid expenses and other current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">4,640</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">3,966</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Current assets of discontinued operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">171</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">100</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.35in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Total current assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">29,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">26,794</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Property, plant and equipment (net)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">387</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">255</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.35in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Total assets</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">29,387</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">27,049</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif"><B>LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Current liabilities:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Accounts payable</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">2,792</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">1,616</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Accrued and other current liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">4,626</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">3,572</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Current liabilities of discontinued operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">75</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">75</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.35in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Total current liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">7,493</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">5,263</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Other liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">206</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">186</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.35in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Total liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">7,699</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">5,449</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Commitments and contingencies</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Stockholders&rsquo; equity:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December&nbsp;31, 2014 and September 30, 2015; 335,273 shares issued and outstanding at December&nbsp;31, 2014 and September 30, 2015. Aggregate preference in liquidation of $3,989,749 at December&nbsp;31, 2014 and September 30, 2015.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">&mdash;</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Common stock, $0.001 par value; 100,000,000 shares authorized at December&nbsp;31, 2014 and September 30, 2015; 23,199,469 and 34,702,910 shares issued and outstanding at December&nbsp;31, 2014 and September 30, 2015, respectively.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">23</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">34</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Additional paid-in capital</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">330,962</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">341,891</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Accumulated other comprehensive loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(480</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(540</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Accumulated deficit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(308,817</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">(319,785</FONT></TD>
    <TD><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.35in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Total stockholders&rsquo; equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">21,688</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">21,600</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.35in; text-indent: -0.1in"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">Total liabilities and stockholders&rsquo; equity</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">29,387</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt double"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt double; text-align: right"><FONT STYLE="font: 10pt Calibri, Helvetica, Sans-Serif">27,049</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>Source: Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Contacts for Cyclacel Pharmaceuticals,
Inc.</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Company: Paul McBarron, (908) 517-7330,
pmcbarron@cyclacel.com</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Investor Relations: Russo Partners
LLC, Robert Flamm, (212) 845-4226, robert.flamm@russopartnersllc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Calibri (Body)"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0P"T P$1  (1 0,1 ?_$ *L  0 " P$! 0$
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M%VEE"INX''[)L:*(S(W=/'G5%0KHI4VP<8[IW9N#>N75G-S252LFI"4ZB$I
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MHQJD)#NG2JCXHR\B*;8QCI@V:G1.8HE.NB'Y@Q&\7&; 7-DM]1Z4,GS.*)[
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M"DC#F;MSJ.)-,B8B4![R*5*NK_@M\:F$]<L(8CR%I/JCF"_8\QC4:Q><I7S
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M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*I%D'!&1<77^9SSJ@,06=L[KZAF+
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0BE.*4XI3BE.*4XI3BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ %P)- P$1  (1 0,1 ?_$ &T  0 # 0$! 0$
M       '" D& P4$"@$!                     !    4#! $$ 0,$ P
M     0(#! 4 !@?5EA=7$2$2$P@B,10503(C%E%""1$!
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MYG'8R&MT#F]7IS..QD-;H'-ZO3F<=C(:W0.;U>G,X[&0UN@<WJ].9QV,AK=
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G,DJKQ!FT/C403^,UD( JI\Y7!O>F3^:_)-']OX./_43D_P"?0/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
